← Back to Search

Cannabinoid Receptor Agonist

Synthetic Psychoactive Cannabinoid Users for Substance Addiction (CB1R in Spice Trial)

N/A

Waitlist Available

Led By Patrick D Skosnik, Ph.D.

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18-55

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change in cb1r availability from baseline throughout one test day

Awards & highlights

CB1R in Spice Trial Summary

This trial is looking at whether people who use synthetic cannabinoids have lower levels of a protein that is involved in the effects of cannabis.

Who is the study for?

This trial is for adults aged 18-55 who currently use synthetic psychoactive cannabinoids and can give written consent. It's not suitable for individuals with less than a high school education or those who cannot undergo MRI due to metal in their body or fear of enclosed spaces.Check my eligibility

What is being tested?

[11-C]OMAR, a substance used in imaging studies, is being tested to see if it shows lower CB1R availability in the brains of people using synthetic psychoactive cannabinoids compared to non-users.See study design

What are the potential side effects?

The description provided does not specify side effects related to [11-C]OMAR; however, as an imaging agent used in PET scans, potential side effects may include allergic reactions or discomfort at the injection site.

CB1R in Spice Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 55 years old.

CB1R in Spice Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change in cb1r availability from baseline throughout one test day

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change in cb1r availability from baseline throughout one test day

This trial's timeline: 3 weeks for screening, Varies for treatment, and change in cb1r availability from baseline throughout one test day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Positron-Emission Tomography

Secondary outcome measures

CogState Battery

Electroencephalogram

CB1R in Spice Trial Design

1Treatment groups

Experimental Treatment

Group I: Synthetic Psychoactive Cannabinoid UsersExperimental Treatment1 Intervention

Synthetic Psychoactive Cannabinoid dependent subjects who are frequent spice/K2 users will receive the radiotracer [11-C]OMAR.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor

1,847 Previous Clinical Trials

2,737,653 Total Patients Enrolled

National Institutes of Health (NIH)NIH

2,696 Previous Clinical Trials

6,952,564 Total Patients Enrolled

National Institute on Drug Abuse (NIDA)NIH

2,465 Previous Clinical Trials

2,618,618 Total Patients Enrolled

Media Library

[11-C]OMAR (Cannabinoid Receptor Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT03539575 — N/A

Substance Addiction Research Study Groups: Synthetic Psychoactive Cannabinoid Users

Substance Addiction Clinical Trial 2023: [11-C]OMAR Highlights & Side Effects. Trial Name: NCT03539575 — N/A

[11-C]OMAR (Cannabinoid Receptor Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03539575 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can octogenarians participate in this research?

"For this trial, the age range for participants is 18 to 55 years old. There are more options available than the present study - 76 clinical trials exist for those under 18 and 255 for seniors aged 65 or above."

Answered by AI

Might I be eligible to join this research initiative?

"This trial is recruiting 15 individuals aged 18 to 55 who are struggling with addiction. In order to qualify, they must provide written consent and demonstrate a lack of higher education (under 12 years)."

Answered by AI

To what extent is participation in this trial widespread?

"Affirmative. As per clinicaltrials.gov, this trial is looking for applicants as of now; it was initially made available on May 1st 2018 and last updated on October 21st 2022. Specifically, 15 candidates are required between a single medical centre."

Answered by AI

Are there still vacancies in this research endeavor?

"Yes, according to information hosted on clinicaltrials.gov this study is actively enrolling participants. The trial was initiated on May 1st 2018 and last updated October 21st 2022; 15 patients are needed from one medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

CB1R in Synthetic Psychoactive Cannabinoids

Deepak C. D'Souza 2018. "CB1R in Synthetic Psychoactive Cannabinoids". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03539575.